Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to $385000.0.

  • Bolt Biotherapeutics' Other Accumulated Expenses rose 321.72% to $385000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $385000.0, marking a year-over-year increase of 321.72%. This contributed to the annual value of $380000.0 for FY2024, which is 3379.79% down from last year.
  • Latest data reveals that Bolt Biotherapeutics reported Other Accumulated Expenses of $385000.0 as of Q3 2025, which was up 321.72% from $500000.0 recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Other Accumulated Expenses ranged from a high of $2.0 million in Q1 2022 and a low of $373000.0 during Q3 2024
  • Its 5-year average for Other Accumulated Expenses is $861210.5, with a median of $826000.0 in 2023.
  • Per our database at Business Quant, Bolt Biotherapeutics' Other Accumulated Expenses soared by 14054.05% in 2022 and then crashed by 5606.6% in 2024.
  • Bolt Biotherapeutics' Other Accumulated Expenses (Quarter) stood at $1.2 million in 2021, then fell by 19.62% to $963000.0 in 2022, then tumbled by 40.39% to $574000.0 in 2023, then plummeted by 33.8% to $380000.0 in 2024, then increased by 1.32% to $385000.0 in 2025.
  • Its Other Accumulated Expenses stands at $385000.0 for Q3 2025, versus $500000.0 for Q2 2025 and $526000.0 for Q1 2025.